Cas:28232-63-5 3-Bromo-5-phenoxypyridine manufacturer & supplier

Chemical Name:3-Bromo-5-phenoxypyridine

CAS.NO:28232-63-5

Synonyms:3-bromanyl-5-phenoxy-pyridine;3-Phenoxy-5-brompyridin;3-bromo-5-phenoxy-pyridine;Pyridine,3-bromo-5-phenoxy;3-bromo-5-(phenyloxy)pyridine;5-bromo-3-phenoxypyridine

Molecular Formula:C₁₁H₈BrNO

Molecular Weight:250.09100

HS Code:2933399090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:311.561ºC at 760 mmHg

Density:1.476 g/cm3

Index of Refraction:

PSA:22.12000

Exact Mass:248.97900

LogP:3.63640

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-bromanyl-5-phenoxy-pyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-bromo-3-phenoxypyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Pyridine,3-bromo-5-phenoxy Use and application,3-bromo-5-(phenyloxy)pyridine technical grade,usp/ep/jp grade.

Related News: The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said. 3-Bromo-5-phenoxypyridine manufacturer From basic chemical raw materials to chemical preparations, complex chemical and physical processes are required. The production of chemical raw materials and intermediates concentrates the main synthetic procedures and technical links, which is the prerequisite and important guarantee for the development of the chemical pharmaceutical industry. 3-Bromo-5-phenoxypyridine supplier The Philippines, the United States and Australia have expanded travel restrictions, temporarily barring noncitizens who have recently traveled to China. 3-Bromo-5-phenoxypyridine vendor The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting. 3-Bromo-5-phenoxypyridine factory From basic chemical raw materials to chemical preparations, complex chemical and physical processes are required. The production of chemical raw materials and intermediates concentrates the main synthetic procedures and technical links, which is the prerequisite and important guarantee for the development of the chemical pharmaceutical industry.